Zymergen Inc.
ZYDelisted Oct 19, 2022- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001645842
Zymergen Inc. was delisted on Oct 19, 2022; its insiders filed their last Form 4 on Oct 21, 2022; 86 institutions reported holding it in 13F filings for Q3 2022, worth $168.1M in total; ARK Invest was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 86
- Q3 2022, +5 vs. previous quarter
- 13F value
- $168.1M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 1
- At the end of Q3 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2021
- $16.7M
- No comparable prior period
- Net income, FY2021
- -$361.8M
- No comparable prior period
- Free cash flow, FY2021
- -$335.9M
- No comparable prior period
- Revenue, Q2 FY2022
- $2.63M
- −55.3% year over year
Superinvestors holding ZY, Q3 2022
Go to the superinvestors tab1 superinvestor reports holding Zymergen Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Zymergen Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | Singh EnakshiChief Financial Officer | SSale | −3.79K | $2.80 | −$10.6K | −0.8%462.2K after | |
| Sep 7, 2022 (view filing) | Sep 2 | 5 days | Singh EnakshiChief Financial Officer | SSale | −3.93K | $2.21 | −$8.68K | −0.8%466.0K after | |
| Sep 7, 2022 (view filing) | Sep 2 | 5 days | Kim MinaChief Legal Officer | SSale | −3.41K | $2.21 | −$7.54K | −1.1%298.4K after | |
| Sep 7, 2022 (view filing) | Sep 2 | 5 days | Serber ZachariahChief Science Officer | SSale | −3.27K | $2.21 | −$7.22K | −0.1%2.55M after | |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Singh EnakshiChief Financial Officer | SSale | −15.4K | $2.27 | −$34.9K | −3.2%470.0K after | |
| Aug 15, 2022 (view filing) | Aug 11 | 4 days | Serber ZachariahChief Science Officer | SSale | −5.43K | $3.91 | −$21.3K | −0.2%2.55M after | |
| Aug 4, 2022 (view filing) | Aug 2 | 2 days | Serber ZachariahChief Science Officer | SSale | −2.97K | $2.61 | −$7.74K | −0.1%2.56M after | |
| Aug 4, 2022 (view filing) | Aug 2 | 2 days | Kim MinaChief Legal Officer | SSale | −3.09K | $2.61 | −$8.08K | −1.0%301.8K after | |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Serber ZachariahChief Science Officer | SSale | −2.80K | $1.32 | −$3.69K | −0.1%2.56M after | |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Kim MinaChief Legal Officer | SSale | −2.92K | $1.32 | −$3.86K | −0.9%304.9K after |
Top 10 13F holders, Q3 2022
See all 86 holdersThe largest institutional positions in Zymergen Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SB Investment Advisers (UK) Ltd | 26,614,219 | $74.0M | 0.57% | 00.0% | Unchanged |
| ARK Investment Management LLCSuperinvestorARK Invest | 7,482,047 | $20.8M | 0.15% | +4,025,529+116.5% | Added |
| Morgan Stanley | 3,344,467 | $9.30M | 0.00% | +1,184,659+54.9% | Added |
| True Venture Partners IV, L.L.C. | 3,024,786 | $8.41M | 100.00% | 00.0% | Unchanged |
| Baillie Gifford & Co | 2,821,956 | $7.84M | 0.01% | 00.0% | Unchanged |
| Data Collective II GP, LLC | 2,448,901 | $6.81M | 80.63% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,436,119 | $6.77M | 0.00% | +555,992+29.6% | Added |
| Ergoteles LLC | 1,007,858 | $2.80M | 0.10% | +649,358+181.1% | Added |
| BlackRock Inc. | 933,154 | $2.60M | 0.00% | +511,943+121.5% | Added |
| Comprehensive Financial Management LLC | 769,477 | $2.14M | 0.06% | 00.0% | Unchanged |